Denying a motion to dismiss Meridian Laboratories’ promissory fraud claim against OncoGenerix USA — a contract manufacturing organization (or CMO) with a laboratory in Mundanjiang, China, that allegedly used false representations about its capabilities and intent to lure Meridian into entering into a service provider agreement (or SPA) to produce large quantities of a drug Meridian developed in Buffalo Grove, Ill., to treat cancer — U.S. District Judge Jorge L. Alonso relied on several Illinois opinions that concluded “a …